Halozyme Therapeutics (HALO) Short term Debt (2013 - 2026)

Halozyme Therapeutics (HALO) has 12 years of Short term Debt data on file, last reported at $208.7 million in Q1 2026.

• Short term Debt for Q1 2026 came in at $208.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $208.7 million (changed N/A YoY), and the FY2022 annual result was $13.3 million, down 85.09% from the prior year.
• Short term Debt retreated to $208.7 million in Q1 2026 per HALO's latest filing, from $710.7 million in the prior quarter.
• Over five years, Short term Debt peaked at $710.7 million in Q3 2025 and troughed at $13.3 million in Q3 2022.
• A 3-year average of $189.1 million and a median of $94.3 million in 2022 frame the typical range for Short term Debt.
• On a YoY basis, Short term Debt climbed as much as 11.08% in 2022 and fell as far as 85.09% in 2022.
• A 3-year view of Short term Debt shows it stood at $13.3 million in 2022, then jumped by 5229.87% to $710.7 million in 2025, then slumped by 70.63% to $208.7 million in 2026.
• Business Quant data shows HALO's Short term Debt at $208.7 million in Q1 2026, $710.7 million in Q3 2025, and $13.3 million in Q4 2022.